​
​

Sensei Biotherapeutics (SNSE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

SNSE Stock Forecast

Sensei Biotherapeutics stock forecast is as follows: an average price target of $5.50 (represents a 995.62% upside from SNSE’s last price of $0.50) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

SNSE Price Target

The average price target for Sensei Biotherapeutics (SNSE) is $5.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $5.00. This represents a potential 995.62% upside from SNSE's last price of $0.50.

SNSE Analyst Ratings

Buy

According to 3 Wall Street analysts, Sensei Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SNSE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Sensei Biotherapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 13, 2024Sudan LoganathanStephens$5.00$1.57218.47%896.02%
Dec 13, 2022-Citigroup$6.00$1.74244.83%1095.22%
Row per page
Go to

The latest Sensei Biotherapeutics stock forecast, released on May 13, 2024 by Sudan Loganathan from Stephens, set a price target of $5.00, which represents a 218.47% increase from the stock price at the time of the forecast ($1.57), and a 896.02% increase from SNSE last price ($0.50).

Sensei Biotherapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$5.00
Last Closing Price$0.50$0.50$0.50
Upside/Downside-100.00%-100.00%896.02%

In the current month, the average price target of Sensei Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sensei Biotherapeutics's last price of $0.50. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
May 13, 2024Stephens-OverweightInitialise
Dec 13, 2022Citigroup-BuyInitialise
Oct 03, 2022Oppenheimer-OutperformUpgrade
Row per page
Go to

Sensei Biotherapeutics's last stock rating was published by Stephens on May 13, 2024. The company Initialise its SNSE rating from "null" to "Overweight".

Sensei Biotherapeutics Financial Forecast

Sensei Biotherapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Sensei Biotherapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SNSE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Sensei Biotherapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict SNSE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Sensei Biotherapeutics's previous annual EBITDA (undefined) of $NaN.

Sensei Biotherapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-2.76M$-2.26M$-2.26M$-4.27M$-7.03M$-7.83M$-7.24M
High Forecast$-2.76M$-2.26M$-2.26M$-4.27M$-5.27M$-7.83M$-7.24M
Low Forecast$-2.76M$-2.26M$-2.26M$-4.27M$-8.79M$-7.83M$-7.24M
Surprise %-------

Sensei Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SNSE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Sensei Biotherapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Sensei Biotherapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SNSE last annual SG&A of $NaN (undefined).

Sensei Biotherapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.11$-0.09$-0.09$-0.17$-0.28$-0.31$-0.29
High Forecast$-0.11$-0.09$-0.09$-0.17$-0.21$-0.31$-0.29
Low Forecast$-0.11$-0.09$-0.09$-0.17$-0.35$-0.31$-0.29
Surprise %-------

According to undefined Wall Street analysts, Sensei Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SNSE previous annual EPS of $NaN (undefined).

Sensei Biotherapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SNSESensei Biotherapeutics$0.50$5.501000.00%Buy
VORVor Biopharma$0.78$6.00669.23%Buy

SNSE Forecast FAQ

Is Sensei Biotherapeutics a good buy?

Yes, according to 3 Wall Street analysts, Sensei Biotherapeutics (SNSE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of SNSE's total ratings.

What is SNSE's price target?

Sensei Biotherapeutics (SNSE) average price target is $5.5 with a range of $5 to $6, implying a 995.62% from its last price of $0.502. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sensei Biotherapeutics stock go up soon?

According to Wall Street analysts' prediction for SNSE stock, the company can go up by 995.62% (from the last price of $0.502 to the average price target of $5.5), up by 1095.22% based on the highest stock price target, and up by 896.02% based on the lowest stock price target.

Can Sensei Biotherapeutics stock reach $1?

SNSE's average twelve months analyst stock price target of $5.5 supports the claim that Sensei Biotherapeutics can reach $1 in the near future.

What are Sensei Biotherapeutics's analysts' financial forecasts?

Sensei Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-22.1M (high $-20.343M, low $-23.858M), average SG&A $0 (high $0, low $0), and average EPS is $-0.88 (high $-0.81, low $-0.95). SNSE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-11.548M (high $-11.548M, low $-11.548M), average SG&A $0 (high $0, low $0), and average EPS is $-0.46 (high $-0.46, low $-0.46).